Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13256434 | 0.87 | DRD2 (0.56) | CHRNA7NPC1RAB9AMEN1KMT2A | |
| SCHEMBL19708630 | 0.85 | GAA (0.57) | CHRNA7MEN1KMT2AFNTAPGGT1B | |
| SCHEMBL2634821 | 0.83 | DDB1 (0.46) | CHRNA7MEN1KMT2AFNTAPGGT1B | |
| SCHEMBL21959945 | 0.82 | PIK3CD (0.54) | NPC1RAB9AMEN1KMT2AFNTA | |
| SCHEMBL1576273 | 0.81 | SIGMAR1 (0.55) | NPC1RAB9AMEN1KMT2AFNTA | |
| SCHEMBL23328305 | 0.81 | DRD2 (0.49) | MEN1KMT2AFNTAPGGT1BFNTB | |
| SCHEMBL23291481 | 0.80 | KMT2A (0.47) | NPC1RAB9AMEN1KMT2AFNTA | |
| SCHEMBL19708633 | 0.79 | ALDH1A1 (0.50) | KMT2A | |
| SCHEMBL2634327 | 0.77 | MAPT (0.51) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL3230978 | 0.77 | CHRNA7 (0.50) | CHRNA7NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618971-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090143381-A1 | MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-06-04 | — | — | US | disclosed |
| US-20080027058-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027058-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF23 | CHRNA7 3685/4885NPC1 1071/4885RAB9A 1651/4885 |
| US-20090143381-A1 | MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS | CFTR, ABCB1, ABCC2 | CHRNA7 2799/4885NPC1 31/4885RAB9A 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.